

# Longevity session

Company name: BioChange Ltd

Website: [www.biochange.life](http://www.biochange.life)

CEO name: Iris Shichor

**Select a CATEGORY:** Medical device

## **EXECUTIVE SUMMARY/INVESTMENT RATIONALE**

BioChange develops CellFoam™, a differentiated scaffold enabling coordinated tissue regeneration by restoring cellular communication. Targeting multi-billion-dollar markets in dental, aesthetics, and regenerative medicine, the company is de-risked through revenue-generating veterinary products with strong clinical validation. Led by a team with three prior exits, BioChange is positioned to scale rapidly through regulatory milestones, strategic partnerships, and global commercialization.

## **CORE TECHNOLOGY**

The body can inherently restore its anatomical blueprint if cells effectively communicate and synchronize. BioChange's CellFoam™ is a unique scaffold mimicking embryonic extracellular matrix architecture. It restores biomechanical signaling between cells, enabling coordinated, multi-tissue regeneration and true functional recovery - without added cells or growth factors - offering a fundamentally new approach to regenerative medicine.

## **PRODUCT PROFILE/PIPELINE:**

BioChange's platform targets multiple organs and indications. Initial products focus on periodontal regeneration, addressing a major unmet need. Future pipeline includes aesthetics, reconstructive surgery, and long-term complex organ regeneration. FDA-cleared veterinary products already demonstrate strong safety and efficacy in clinical studies and real-world use. Partnerships with global dental and aesthetics leaders are actively pursued.

## **BUSINESS STRATEGY:**

BioChange follows a de-risked strategy: veterinary revenues support human clinical and regulatory advancement. CellFoam™ is a scalable platform across dental, aesthetic, and regenerative markets. The company combines distributor-led commercialization, licensing, and strategic partnerships to maximize reach and value, focusing on high-margin products, efficient manufacturing, and a strong global IP portfolio.

## **WHAT'S NEXT?**

Key milestones include FDA clearance for dental products targeted for 2027, continued clinical validation, and expansion into new indications. BioChange is strengthening global partnerships and scaling manufacturing capabilities. Financial strategy includes

product revenues, distribution agreements, and selective capital raises to accelerate commercialization and broaden the pipeline.